MSc in Finance and Investment

University of Hull, United Kingdom

Over 15 years of in-depth industry experience.

Core Expertise:

Full-cycle private equity fund management, risk control system development, cross-border capital operations, and government-guided fund liaison. Known for a compliance-driven, value-oriented approach across the entire "fundraising–investment–portfolio management–exit" value chain, empowering the full lifecycle of both funds and portfolio projects.

Doctorate in Business Administration (DBA) from Paris School of Business

One of China's 30 Most Influential Investors, Honorary President of the Hong Kong Association of Pharmaceutical Innovation, Founding Member of the Investment Committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), Member of the BayHelix Group, and Distinguished Lecturer at Duke Kunshan University.

With over a decade of experience in the investment industry, he has focused on the biopharmaceutical sector, contributing to the advancement of the pharmaceutical industry. He has led investments in Heyuan Biosciences, Chipscreen Biosciences, Ascentage Pharma, Frontier Biotechnologies, Genuine Biotech, Qyuns Therapeutics, and others.

His accolades include:

• CHC · Top 50 Most Influential Investors of the Year

• FOF Weekly · Top 20 Best Healthcare Investors of 2023

• CHC · Top 50 Most Influential Investors of 2022

• ChinaVenture · Top 100 Chinese Best Venture Capitalists of 2021

• Best Investor in the Medical and Health Industry 2020

• China Financial Person of the Year Top 5 2019

Master's Degree

Durham University, United Kingdom

Former Role:

China International Capital Corporation (CICC)

Experience:

With multiple years of investment banking experience, [I/he/she] has served a number of financial institution headquarters and state-owned listed companies, and been deeply involved in the investment operations of multiple projects.

• Bachelor of Arts in Economics, University of California, San Diego (UCSD)

• Member of the Inaugural Cohort of Young Investors of H50 (China Healthcare Investment H50)
  2023 Forbes China · Top 100 Young Returnee Elites
  2025 Fortune China · 40 Under 40 – Most Promising Business Elites
  Consecutive Honoree, U40 Young Elite List
  40 Under 40 – Best Direct Investment Fund Young Investors
  2022 Supernova · Top 50
  Young Investor in Healthcare

• Initiated and deeply participated in investments in star projects including OBiO Technology, Asieris Pharmaceuticals, Insight Lifetech, and Harbour BioMed

• Previously served in the Asset Management Department of China International Capital Corporation (CICC)

Hong Kong SFC Type 9 Responsible Officer (RO)

Master of Pharmacy (M.Pharm.)

China Pharmaceutical University

Former Roles:

Director of Pharmaceutical & Healthcare Business, Strategic Management Department, China Resources Group

General Manager of Investment & Development, China Resources Life Sciences Group

Production & Operations Director, GlaxoSmithKline (GSK)

With over a decade of experience in financial management and capital operations across listed companies (Kingdee International, Wiscom System) and private equity funds. Holds a Bachelor's degree in Accounting. Deeply involved in investor relations, brand strategy, and post-investment exit management of core projects, driving diversified financing strategies and maximizing project value realization.

• Ph.D., Zhejiang University; Postdoctoral Fellow, Baylor College of Medicine; Adjunct Professor, Zhejiang University School of Medicine

• Principal Investigator (PI) at an independent laboratory in the United States; Supervisor for doctoral students and postdoctoral fellows; Recipient of multiple research grants, including the R01 grant from the National Institutes of Health (NIH)

• A decade of experience in the pharmaceutical industry; previously worked at Lexicon Pharmaceuticals (USA), Hisun Pharma, and others; contributed to the market approval or clinical trial advancement of multiple products

• Former Partner at Yingke Capital; full-spectrum coverage of pharmaceuticals, medical devices, IVD, and CXO; invested in over 30 portfolio companies

Pharmacy Doctor, Fudan University,

Research and investment in the field of anti-tumor drugs,

Experiences in consulting and healthcare investment,

Overseas mergers and acquisitions & innovative drug investment

Master's Degree

Durham University, United Kingdom

Former Role:

China International Capital Corporation (CICC)

Experience:

With multiple years of investment banking experience, [I/he/she] has served a number of financial institution headquarters and state-owned listed companies, and been deeply involved in the investment operations of multiple projects.

Bachelor of Arts in Economics

University of Washington, U.S.A.

Ten years of experience in financial management and corporate operations.

Former Role:

Group Finance Department, Huawei Technologies Co., Ltd. — with deep expertise in financial coordination, internal control, and organizational management.

Current Role:

Member of the Management Decision Committee, with overall responsibility for corporate financial management, human resources & administration, and digital transformation initiatives. Committed to advancing the standardization of corporate governance systems and enhancing organizational effectiveness.

Bachelor's degree in Pharmacy from Shanghai Jiao Tong University and Master's degree in Finance from Durham University, UK, with a multidisciplinary background. Five years of investment experience, specializing in medical devices and new materials. Successfully exited 4 investments, including 2 IPO projects.

Master's degree in Investment from Central University of Finance and Economics, and serves as an off-campus graduate advisor. Over ten years of experience in biomedical investment, with backgrounds in the investment department of a listed pharmaceutical company and a central SOE private equity firm. Has led investments and incubations in over 20 projects across innovative drugs and medical devices, with more than 6 exits through IPOs, M&A, and equity transfers. Has initiated and established multiple healthcare funds.

Ph.D. in Chemistry from the University of Texas at Austin. Nearly ten years of experience in biomedical investment in both China and the United States. Specializes in investments in cutting-edge biotechnology fields such as innovative drugs and synthetic biology.

MSc of Biology, Sun Yat-Sen University, Focuses on gene, cell therapy, high-end medical device research and investment, many years of VC/PE investment experience, with > 15 successful investment cases, including 5 IPO projects

Ph.D. in Chemistry

The University of Texas at Austin, U.S.A.

Multi-year cross-border biopharmaceutical investment experience (China & U.S.).

Core Focus:

Innovative drugs, synthetic biology, and other cutting-edge biotechnology sectors.

Additional Background:

Investment experience in the private equity secondary market within the healthcare sector.

Ph.D. in Neurobiology (USTC) and B.E. in Bioengineering (CUMT), offering a unique interdisciplinary background spanning life sciences and engineering. Focuses on PE investment in innovative drugs and high-value medical devices, with multiple closed deals in the sector.

Ph.D. in Life Sciences from Nankai University, specializing in enzyme-catalyzed biosynthesis and nucleic acid aptamers. Authored multiple SCI papers and contributed to several patents and industry standards.